Amplia Therapeutics Ltd has released a press release.
Capital Raising - Investor Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
In the deck
Story so far
Earlier from Amplia Therapeutics
- Entitlement Offer to Fund Phase 1 Clinical Trial
- Preliminary Toxicology Studies Support Phase1 Clinical Trial
- Preliminary Final Report - YE 31 March 2020
- FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis
- Quarterly Activities Report - March 2020 Qtr
Later from Amplia Therapeutics
- Institutional Entitlement Offer Completed
- Nucleus Network Appointed to Conduct Phase 1 Clinical Trial
- Quarterly Activities and Cashflow Reports - June 2020
- Amplia Receives Ethics Clearance fo Conduct Phase 1 Trial
- First Human Dose in Phase 1 Clinical Trial of AMP945
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics